cyrilzakka/clinical-trials huggingface dataset:
Effect of Kinesiotape Versus Myofascial Release on Postnatal Low Back Pain

This study aims to determine the difference between the effect of kinesiotape and myofascial release in the treatment of postnatal low back pain.

Postpartum back pain may occur in up to 44% of women after childbirth. People who have chronic back pain may have a limited range of motion and/or tenderness upon touch.

Therapeutic KT can benefit a wide variety of musculoskeletal and sports injuries, plus inflammatory conditions. According to the Kinesiotape Method Manual, this traction promotes an elevation of the epidermis and reduces pressure on the mechanoreceptors located below the dermis, thereby reducing nociceptive stimuli and low back pain.

Myofascial release (MFR) is a treatment that uses gentle pressure and stretching to facilitate the release of fascial restrictions caused by accidents, injury, stress, repetitive use, and traumatic or surgical scarring.

Myofascial release is a form of soft tissue therapy used to treat somatic dysfunction and accompanying pain and restriction of motion. This is accomplished by relaxing the contracted muscle, increasing circulation, increasing venous and lymphatic drainage, and stimulating the stretch reflex of muscles and overlying fascia so, reducing low back pain.

Eligibility Criteria:
Inclusion Criteria:

* Their ages will be ranged from 20 to 35 years old.
* Their body mass index (BMI) will not exceed 30 kg/m2.
* Women will be postnatal period by 6-8 weeks.
* All women will be diagnosed by the physician as postnatal low back pain.

Exclusion Criteria:

* Spinal fracture or any other neurological disorders.
* Lumbar disc herniation or degenerative disc disease
* Lumbar spinal stenosis from lumbar disc herniation, degenerative joint disease, or spondylolisthesis
* Women with BMI exceed 30 kg/m2.
* Patients who have polyneuropathy or other neurological disorders.
* Skin disease interferes with kinesiotape or myofascial release application.
Development, Attention, and Inhibition Study

The goal of this clinical trial is to test the associations of young children's early life experiences with delaying behaviors and links with later life outcomes. The main questions it aims to answer are:

* Do experiences with waiting in early childhood predict delaying behavior in context-specific ways?
* Are links between delaying behavior and life outcomes impacted by social conventions, effort and choices around delaying, or other behaviors?

Participants will:

* Complete two delaying tasks with either a sweet or wrapped gift
* Complete three "Simon says"-like games that measure inhibition, cognitive flexibility and proactive control
* Answer a set of questions about academic readiness
* Answer a set of questions about social conventions
* Complete a waiting game on the computer while a camera records eye movements
* Parents will answer questions about their child's behaviors and experiences at home
* Participants will return after 1 year to repeat a subset of these measures

In sessions 1 and 2, 4-6-year-olds will complete a delay of gratification task (randomly assigned to one of two groups, to delay with either a sweet or a wrapped gift), the NASA Load Index to report perceived demand and effort for the delay of gratification task, a computerized delay choice measure (while pupillometric data is collected), a Go/No-Go task, the NIH Toolbox Dimensional Change Card Sort, a Track-It task, a task measuring sensitivity to social conventions, and Woodcock-Johnson IV Tests of Achievement. Parents will complete the Child Behavioral Checklist (CBCL), the Child Behavior Questionnaire (CBQ), the REEF executive function questionnaire, and questionnaires about demographics and children's experiences waiting at mealtimes, when opening gifts, and in other contexts.

In session 3 (1 year after sessions 1 and 2), participants and parents will repeat the measures from sessions 1 and 2.

Eligibility Criteria:
Typically developing children will be recruited. Participants will be pre-screened for developmental disorders.
Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask

Optiflow™ may provide an opportunity to prolong apnea time in the morbidly obese patient population. This study will examine whether Optiflow can do this, and compare the pre-oxygenation with Optiflow to the pre-oxygenation achieved with face mask.

The use of high flow nasal cannula (HFNC) originated in neonatal care, and has become widespread in its application for patients that are high risk for hypoxemia, both in critical care and emergency settings. Therefore, high flow nasal oxygenation continues to be studied in airway management for preoxygenation, as well as maintenance of oxygenation in airway procedures. Optiflow™, a humidified high flow nasal cannula, has already been shown to be useful in preventing desaturation during intubation in ICU patients versus the non-rebreathing mask, in addition to, prolonging safe apnea time in patients with potential difficult airways. Additionally, preoxygenation with HFNC prior to intubation of patients in hypoxemic respiratory failure has also been shown to decrease desaturation during apnea compared to preoxygenation with traditional bag valve mask. The morbidly obese patient presents a separate group of challenges to the anesthesiologist in regards to mask ventilation and intubation. Obesity (along with other factors) has been shown to contribute to difficulty with mask ventilation. Obese patients have altered respiratory physiology, including decreased functional residual capacity, increased oxygen consumption and lower tidal volumes, as compared to the non-obese patient. These factors contribute to obese patients potentially having a shorter apnea time before desaturating during induction of general anesthesia, as compared to the non-obese patient. Weight is inversely correlated with safe apnea time. Optiflow™ may provide an opportunity to prolong apnea time in the morbidly obese patient population. If demonstrated to be efficacious as a method for preoxygenation and prolongation of apneic time, this could provide a safer environment for intubation in this particular patient population.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients (≥ 18 years old) undergoing elective surgery requiring general anesthesia
* BMI \> 40 kg/m2
* American Society of Anesthesiology (ASA) Physical Status II-III

Exclusion Criteria:

* Chronic hypoxemia (SpO2 \<94% on room air or on home oxygen)
* Acute respiratory failure
* Coronary artery disease and/or congestive heart failure
* Moderate-Severe pulmonary hypertension and/or RV dysfunction
* Full stomach (recently eaten)
* Pregnancy
* Chronic pulmonary disease (specifically COPD or interstitial disease, NOT asthma)
* Respiratory tract pathology
* Facial Abnormality
* American Society of Anesthesiology (ASA) Physical Status IV-V
A Prospective Cohort Study of for Surgical Treatment of Irreducible Atlantoaxial Dislocation

The management of irreducible atlantoaxial dislocation associated is challenging. Direct posterior distraction technique we proposed in 2010 could achieve satisfactory reduction. In 2020, we modified this technique and proposed a posterior intra-articular distraction technique. The intra-articular distraction technique could theoretically achieve satisfactory reduction and fusion. However, its superiority has not been proven. Therefore, we design a prospective study to compare the reduction rate and fusion rate of different strategies.


Eligibility Criteria:
Inclusion Criteria:

CT indicated atlantoaxial dislocation Agree with the operation plan Agree to be followed up

Exclusion Criteria:

The pathology is traumatic or RA Underwent operations in occipital-cervical region before With mortal diseases Without ability to sign papers
Localising Occult Prostate Cancer Metastases With Advanced Imaging TEchniques

The investigator prospectively compare diagnostic concordance of whole body multi---parametric Magnetic Resonance Imaging (MRI) with current conventional multi---modality reference standard imaging (CT scan, isotope bone scan +/--- PET---CT scan) for staging of prostate cancer patients with biochemical relapse following external beam radiotherapy or brachytherapy of locally advanced prostate cancer.

The investigators have developed and assessed the feasibility of performing whole---body multi---parametric MRI for staging metastatic disease. The investigators hypothesize that a whole body multi---parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. Investigators therefore propose a comparative trial of conventional imaging verses whole---body multi---parametric MRI within this population of men. The investigators would further like to explore whether heterogeneity between metastases of multi---parametric MRI signals can predict men unlikely to respond to ADT. The investigators aim to enhance the main study by exploratory work on exosome, pathway and genomic analysis, the results of which could lead to complimentary imaging / non---imaging biomarker combinations of clinical utility for patient stratification. Finally the investigators will perform a health economic analysis to assess the cost---effectiveness of whole---body multi---parametric MRI for metastatic disease staging compared with conventional staging with computed tomography and bone---scans.

Eligibility Criteria:
Inclusion Criteria:

* Men who have undergone previous external beam radiotherapy or brachytherapy with or without neo---adjuvant/adjuvant hormone therapy
* Men who have radiorecurrent disease defined by biochemical failure - Phoenix definition (PSA nadir + 2 ng/mL)

Exclusion Criteria:

* Men unable to have MRI scan, or in whom artefact would significantly reduce quality of MRI
* Men unable to give informed consent
D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain

D-cycloserine may help lessen pain and other symptoms of peripheral neuropathy caused by chemotherapy. It is not yet known whether D-cycloserine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy.

This randomized, double-blind, placebo-controlled clinical trial was designed to study D-cycloserine at 2 different doses to see how well each works compared to the other and to a placebo in treating cancer patients with peripheral neuropathy caused by chemotherapy.

This is a randomized, double-blind, placebo-controlled study. Initially, patients were randomized to 1 of 2 treatment arms (D-cycloserine 250 mg twice daily or placebo twice daily), and treated for up to 4 weeks in the absence of unacceptable toxicity.

Later, the design was changed to randomize patients to 1 of 3 arms as follows:

* D-cycloserine 50 mg twice daily for up to 12 weeks
* D-cycloserine 200 mg twice daily for up to 12 weeks
* Placebo twice daily for up to 12 weeks

Eligibility Criteria:
Inclusion Criteria:

* Patients will be at least 18 years of age.
* Patients will be experiencing moderate to severe peripheral neuropathic pain
* Patients may be on chronic adjuvant pain medications such as antidepressants but must be on stable doses for at least one week prior to admission.
* Patients may be taking concurrent opioids but they must be willing to allow us to monitor their opioid use while on the trial.
* Patients must have chronic peripheral neuropathic pain will be defined as pain of 3 or more months duration which began in association with chemotherapy.
* Patient's will have bilateral peripheral neuropathic pain symptoms primarily involving the feet
* Patients must have breast cancer (any stage)
* Patients must be able to read and speak English and provide informed consent.
* Patients may be receiving chemotherapy as long as the agents are not known to cause a peripheral neuropathy.
* Patients must have an ECOG Performance Status \< 3 and be able to attend the physician study visits
* Patients must not concurrently use gabapentin or pregabalin or must be willing to wean off their anti-convulsant medications prior to starting the trial.
* Patients may have diabetes mellitus (type 1 or 2) as long as there is no preexisting neuropathy.

Exclusion criteria:

* Patients will not have secondary cause of neuropathic pain including: HIV/AIDS,traumatic injury, or a personal history of non chemotherapy-induced neuropathy.
* Patients will not have a history of major depression or severe anxiety.
* Women of childbearing age will agree to take measures to prevent pregnancy and will not breast-feed while on the study medication. Women who are currently pregnant will not be invited to participate in this study.
* Patients will not have a history of seizures.
* Patients cannot be currently receiving antibiotic therapy for tuberculosis (e.g. isoniazid).
Efficacy of Brisk Walking in Parkinson's Disease

Parkinson's disease (PD) is the second most common neuro-degenerative disease in older people. Falls are common among people PD with the incidence rate up to 70% and have strong associations with the severity of the disease, balance impairment, and freezing of gait.The abnormal gait characteristics include reduction in stride length, gait speed and arm swing, and increase in cadence. Gait training, balance training, aerobic training, Tai chi and dance training are common types of physical rehabilitation for PD. Brisk walking is a way of walking with a pace faster than normal, and it can improve dynamic balance for senior men and balance function for chronic stroke clients.

Brisk walking also promotes cardiopulmonary fitness and walking endurance in elderly women, healthy middle-age and older adults, active elderly men and chronic stroke clients. Our previous pilot randomized controlled trial on the effects of a 6-week home-based brisk walking program indicates that it is feasible and safe for the early PD population with improved walking capacity measured by 6-minute walk distance. The positive effects could carry over to 6 weeks after treatment completion. Up-to-date, the short- and long-term effects of brisk walking in improving balance and gait performance, and functional capacity in people with PD have not yet been well investigated. In order to promote their balance and functional capacity in longer term, more sustained training and better exercise adherence may be necessary.


Eligibility Criteria:
Inclusion Criteria:

* Parkinson disease diagnosed by neurologist with Hoehn \& Yahr stage 2 or 3
* Having a 30-meter walking ability

Exclusion Criteria:

* Significant neurological condition (other than Parkinson's disease)
* Musculoskeletal conditions affecting gait, balance or upper limb functions
* Had received deep brain stimulation surgery
* Cognitive impairment with Montreal Cognitive Assessment score \<24
* Present with on-off motor fluctuations.
Effect of Remote Ischemic Preconditioning on Cerebral Circulation Time in Patients With Severe Carotid Artery Stenosis (RIP-CCT)

Cerebral circulation time in patients with severe carotid artery stenosis was found to be associated with hyperperfusion syndrome. Remote ischemic preconditioning can change the ability of cerebral autoregulation. The prospective, randomized controlled, blind outcome evaluation, multi-center study aimed to investigate the effect of remote ischemic preconditioning on cerebral circulation time in patients with severe carotid artery stenosis.


Eligibility Criteria:
Inclusion Criteria:

* age 18 years or older, regardless of gender;
* patients with severe carotid stenosis eligible for stenting (70-99% stenosis confirmed by DSA);
* non-responsible vessel stenosis \<50% if bilateral carotid stenosis or combined posterior circulation stenosis is present;
* first DSA suggestive of ≥ 0.8 seconds difference (CCT on the affected side - CCT on the healthy side);
* baseline modified Rankin Scale (mRS) ≤ 2 points.
* signed the informed consent form.

Exclusion Criteria:

* baseline mRS ≥ 3 points;
* severe long-segment calcification of the carotid artery, severe distortion of aortic arch branches, anatomical variation of the aortic arch, and etc, which are not suitable for stenting
* spontaneous intracranial hemorrhage within 12 months;
* previous severe stroke or myocardial infarction within 3 months;
* active bleeding and coagulation disorders, which is contraindication to heparin and antiplatelet agents;
* a large intracranial aneurysm that cannot be treated simultaneously;
* severe insufficiency of vital organs such as the heart, lungs, liver and kidneys, or malignant tumors with an expected survival cycle of less than six months;
* total occlusion of carotid artery without obvious cerebral ischemic symptoms
* unable to tolerate anesthesia;
* severe dementia;
* uncontrolled hypertension ;
* allergy to contrast media;
* pregnancy;
* being involved in studies with other drugs or instruments, etc;
* contraindications to remote ischemic preconditioning, such as those with more severe soft tissue injuries, fractures or vascular injuries in the upper extremity, or peripheral vascular lesions in the distal upper extremity.
Age Related Effects Consuming Phaeodactylum Tricornutum

Investigation of the microalgae Phaeodactylum as food with regard to the uptake of omega-3 fatty acids and effects on various blood parameters in relation to age.

Bioavailability and excretion of nutrients and their effects on fatty acid status and inflammatory markers.

Due to a multifaceted redesign of all areas of life, older people face many nutritional challenges, such as cognitive change, sarcopenia and micronutrient deficiency. In addition to age-associated diseases, cognitive decline is usually a precursor to neurodegenerative processes, such as Alzheimer's disease. The full molecular mechanisms are still unknown, but classic aging mechanisms, such as oxidative stress and subclinical inflammation, play a role. Due to the changed life situation, there is a reduced need for energy, while the need for nutrients remains, which greatly increases the risk of malnutrition in old age. This results in an increasing prevalence of sarcopenia. The decrease in muscle mass and strength leads to functional limitations in the elderly and also promotes oxidative stress. This increases the need for antioxidant nutrients such as carotenoids and vitamins. Studies show that age-related chronic subclinical inflammation, such as occurs in the context of an omega-6 fatty acid (-FS) emphasized diet, plays a central role in the pathogenesis of age-associated diseases

Due to this, the microalgae PT could be a goud supplier of nutrients like omega-3 FS, especially eicosapentaenoic acid (EPA), which is otherwise found mainly in fatty fish, and Fucoxanthin, an antioxidant. The investigator study the change of omega-3, -6 and -9 FS in blood plasma, in erythrocytes, as well as the change of fucoxanthin and beta-carotene. The investigator measure blood parameters for safety and control the influence on the intestinal barrier.

Eligibility Criteria:
Inclusion Criteria:

Age ≥60 ≤90 years, weight ≥50 kg, generally healthy

* Signed informed consent form
* Willingness to follow the prescribed diet for the duration of the study
* No participation in any other clinical trial (current or within the last 30 days)

Exclusion Criteria:

* Taking intestinal therapeutics, antibiotics, immunosuppressants or similar. (if necessary, decision on a case-by-case basis)
* Pregnancy/breastfeeding
* Relevant violations of the dietary protocol
* Occurrence of relevant diseases (if necessary, individual case decision)
* Withdrawal of consent
* Placement in a clinic or similar facility due to official or court order
Management of Closed Diaphyseal Displaced Leg Fractures in Children and Adolescents

Most displaced tibial shaft fractures in pediatric patients have traditionally been treated after reduction by cast immobilization with good long-term results. Recently, there has been a growing trend towards surgical intervention by osteosynthesis from the outset. This study aims to describe the results of orthopedic treatment and osteosynthesis from the outset.


Eligibility Criteria:
Inclusion Criteria:

* Minor subject (under 18 years old)
* Subject treated at the HUS, between June 1, 2004 and April 31, 2024, for a fracture of the displaced diaphysis of the tibia treated orthopedically or by osteosynthesis reviewed after more than 6 months
* Absence of written opposition in the medical file of the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes.

Exclusion criteria:

* Presence of opposition from the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes.
* Non-displaced and/or displaced fracture not located at the level of the tibial diaphysis
* Open fracture
* Incomplete or unusable file
Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen

The purpose of this study is to determine whether sequential application of low-dose short-term sunitinib and chemotherapy is effective in the treatment of non-small cell lung cancer after failure of conventional therapy. Safety of this regimen will also be evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Histologic or cytologic diagnosis of stage IIIB/IV NSCLC
* ECOG PS: 0,1
* Unidimensional or bi-dimensional measurable disease
* Receive prior treatment including first-line platinum-based chemotherapy, standard second-line chemotherapy and 1 EGF/EGFR inhibitor
* Evidence of disease progression
* Life expectancy \>12 weeks
* Neutrophils \> 1.5 109/l, Platelets \> 100 109/l, Hemoglobin \> 9g/dl, Total bilirubin \< 1.5 UNL, AST (SGOT) and ALT (SGPT) \< 2.5 UNL, Alkaline phosphatases \< 5 UNL, Creatinine \< 1 UNL

Exclusion Criteria:

* Pre-existing hemoptysis of a severity \> grade 3 by NCI CTCAE criteria within 4 weeks prior to study entry
* Uncontrolled hypertension
* CHF, angina or arrhythmias
* LVEF \< 1 UNL
* Existing a second malignancy within 5 years
* Infected with HIV
Unattended In-home Sleep Recording: A Pilot Study

Laboratory studies have found that insufficient sleep duration and impaired sleep quality are associated with disease risk, including obesity, diabetes and heart disease. The limitation to the laboratory studies is that they are conducted in artificial environments that do not reflect real-world behavior. Although the epidemiologic studies do reflect habitual behavior, the vast majority of them rely on self-reported measures of sleep, which are only moderately correlated with objective measures of sleep.. The next logical step in the examination of sleep's role in cardiometabolic health is to conduct objective, detailed measures of sleep in people's homes. This project is a pilot study that will develop ideal methodologies for recording sleep in the home environment. Because there is currently is a gap between laboratory models of sleep loss and real world conditions, the ultimate goal of this research is to expand our work on sleep and cardiometabolic health outside of the laboratory. Given the strong evidence for a link between impaired and insufficient sleep and increased disease risk, it is critical that we understand how people sleep in their daily lives and what factors can impact sleep. This project will record sleep in people's homes using ambulatory polysomnography recordings and wrist actigraphy.


Eligibility Criteria:
Inclusion Criteria:

* Must have had a polysomnography recording at the University of Chicago.

Exclusion Criteria:

* None.